Biologic therapies in neurology: Clinical promise, economic divide

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board. MedLink acknowledges using artificial intelligence to assist in the creation of blog posts.

The advent of biologic therapies in neurology—monoclonal antibodies for migraine, NMOSD, multiple sclerosis, and Alzheimer disease—has introduced valuable tools for disease modification and symptom control. However, their high cost remains a persistent barrier to access. Neurologists increasingly face the challenge of recommending clinically effective treatments that are unaffordable for many patients.

Pricing: a system without transparency

Biologic pricing remains opaque. Unlike generics, biologics are patent-protected and costly to develop and manufacture. Factors influencing pricing include:

• Perceived therapeutic innovation.
• Orphan or accelerated approval designations.
• Projected value based on quality-adjusted life years.
• Competition and alternatives.

There is no fixed pricing formula. Launch prices often anticipate third-party payer absorption, and third-party coverage does little for uninsured or underinsured patients.

Do government negotiations actually lower prices?

Although policy changes made under the Inflation Reduction Act are framed as enabling Medicare drug price negotiation, this is somewhat misleading. Rather than true negotiation in the market sense, the Inflation Reduction Act allows the Centers for Medicare & Medicaid Services to arbitrarily cap prices for a limited number of high-expenditure drugs. Manufacturers that do not comply face significant penalties.

This represents price regulation more than negotiation but applies only to selected Medicare-covered drugs. Medicaid programs, administered at the state level, also cap prices but remain constrained by statutory frameworks. For patients paying out of pocket, these caps do not apply—often leaving them with the full list price unless charity care or independent assistance is secured.

The uninsured and underinsured

Patients lacking comprehensive insurance may face list prices of $10,000 to $30,000 or more per year. Although pharmaceutical companies offer patient assistance programs or copay cards, these often exclude Medicare beneficiaries due to anti-kickback statutes and may require complex applications with inconsistent eligibility.

What physicians can do

Neurologists can support patients by:

• Referring patients to financial counseling or specialty pharmacy services early.
• Submitting timely prior authorizations and appeals when denials occur.
• Connecting patients with nonprofit foundations, state-based aid, or hospital-supported medication assistance programs.
• Using sample programs when available to bridge short-term access gaps.
• Advocating institutionally or locally for formulary inclusion and broader coverage.

Clear documentation of medical necessity and side-effect history from prior therapies is often critical in navigating payer barriers.

Price controls versus free-market innovation

This ongoing debate is central to the biologics landscape:

Advantages of price regulation:

• Price regulation can improve access and reduce financial toxicity.
• Price regulation may stabilize healthcare budgets and ensure equity in life-saving therapies.

Risks of regulation:

• Regulation may reduce incentives for innovation, particularly for rare or high-risk targets.
• Regulation could shift research and development investments toward more profitable markets.

Conversely, free-market pricing can encourage rapid therapeutic innovation, but those benefits may be out of reach to the under-resourced until patents expire.

Looking ahead

The entry of more biologics into neurology will likely continue, bringing both therapeutic progress and economic strain. Neurologists may counsel patients on how to take advantage of available resources and may serve as advocates on their behalf.

Related MedLink Neurology content:

• Podcast: The Neurotransmitters: Thoughts on the Cost of Neurology Medications
• Blog: Navigating the financial and ethical challenges of high-cost biologicals in neurology and Evaluating the cost and benefit of amyloid pet scans and new Azheimer disease therapies: A financial and clinical perspective

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.